Impact of HIV and Its Treatment on Reverse Cholesterol Transport

This trial is enrolling now. Depending on eligibility and available places in your area, you may be able to enrol in this trial.

About this trial

This is an observational study, looking at the effect HIV treatment has on the health of our heart. The investigators are comparing how well cholesterolAn essential component of cell membranes and nerve fibre insulation, cholesterol is important for the metabolism and transport of fatty acids and the production of hormones and Vitamin D. Cholesterol is manufactured by the liver, and is also present in certain foods. High blood cholesterol levels have been linked to heart disease and may be a side effect of some anti-HIV medications. is processed by those not on therapy with those who are on treatment. They are also comparing those on NNRTI-based regimens with those on PIA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate.- based ones.

NOVEMBER 2009 UPDATE: Recruitment for the PI armAny of the treatment groups in a randomised trial. Most randomised trials have two "arms," but some have three "arms," or even more. is still open.

Background information

Cardiovascular disease is increasingly recognized to be a significant cause of morbidity and mortality among people with chronic HIV infection in the current era of effective antiretroviral therapy. Those treated with antiretroviral therapy have increased traditional cardiovascular risk factors, but whether HIV infection in and of itself confers a significant increase in cardiovascular risk is largely unknown.

Official title:

Impact of HIV Infection and Treatment With Highly Active Antiretroviral Therapy on Reverse Cholesterol Transport

What is this trial studying?

se_management

Start date:

June 2005 (This may be the proposed or expected start date for trials which have not yet started.)

How many participants will this trial enrol?

75 (The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.)

Links to further information:

• http://clinicaltrials.gov/ct2/show/NCT00168233?term=HIV+AND+Australia&rank=19

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

• At least 18 years old
• Have never taken HIV treatments
• This trial is for men only

You will not be eligible to participate in this trial if you meet any of the following criteria:

• Treatment with any form of lipid lowering drugs, including fish oils or a Body Mass Index greater than 27.

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

If you are interested in enrolling in this trial

Before making the decision to participate in any clinical trial, NAPWA recommends that you discuss the potential benefits and risks of participation with your treating doctor. Your doctor can also provide advice about your eligibility to participate in the trial.

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

Before making the decision to participate in any clinical research, visit the NAPWA website for background information on participating in clinical research.

Contact NAPWA if you have any questions or comments about this trial.